Target intelligence / Profile preview

Novel transcript, antisense to CCDC141 and TTN (ENSG00000287149)

Target
ENSG00000287149
Molecular classification
Long non-coding RNA (lncRNA)
01

Overview

ENSG00000287149 is a **long non-coding RNA transcript antisense to CCDC141 and TTN**, identified in genomic annotations and affiliated with the lncRNA class[5][1]. "Antisense" indicates that its sequence is complementary to sequences in the CCDC141 and TTN genes, suggesting a possible role in transcriptional or post-transcriptional regulation. Although antisense lncRNAs are implicated in gene expression control, chromatin architecture, and alternative splicing—such as the well-studied TTN-AS1, which regulates TTN splicing in heart tissue[2][3]—there is no evidence that ENSG00000287149 shares these roles or clinical relevance at present. The transcript lacks known protein-coding capacity, established biological functions, disease associations, or therapeutic interactions. As a genomic annotation, it primarily serves as a subject for future research into the regulatory landscape of the CCDC141 and TTN loci.

Other names
ENSG00000287149Novel transcript, antisense to CCDC141 and TTN
02

Mechanism of action

None known. No drugs or interventions target this specific lncRNA.

03

Biological functions

Currently unknown. General lncRNA functions may include regulation of gene expression, chromatin modification, or alternative splicing, but there is no direct evidence for this specific transcript.
04

Disease associations

Currently unknown. There is no documented association with specific indications (e.g., cancer, heart disease, neurodegeneration) for ENSG00000287149.
05

Safety considerations

None identified. lncRNAs generally present challenges in therapeutic targeting due to limited tissue-specificity and unknown off-target effects, but no safety issues are directly attributable to this transcript.

Beyond the preview

Go deeper on Novel transcript, antisense to CCDC141 and TTN (ENSG00000287149).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to CCDC141 and TTN (ENSG00000287149).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call